Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PhRMA Reconsiders Medicare Stance For 2000: Incremental Reform Weighed

Executive Summary

The linchpin legislative policy decision facing PhRMA for 2000 is whether to endorse an incremental drug benefit that stops short of comprehensive Medicare reform.

You may also be interested in...



PhRMA Moves To Head Off Clinton Assault; Considers Incremental Rx Benefit

The Pharmaceutical Research & Manufacturers of America is attempting to defuse some of the Clinton Administration's rhetoric on drug costs to the elderly ahead of the State of the Union address.

PhRMA Moves To Head Off Clinton Assault; Considers Incremental Rx Benefit

The Pharmaceutical Research & Manufacturers of America is attempting to defuse some of the Clinton Administration's rhetoric on drug costs to the elderly ahead of the State of the Union address.

Canadian Price Controls May Become Higher Priority For PhRMA

The impact of international pharmaceutical price controls on the U.S. Medicare debate may be leading PhRMA to step up its international lobbying efforts, particularly in Canada.

Related Content

UsernamePublicRestriction

Register

PS035177

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel